What is pulmonary embolism?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 24, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Pulmonary Embolism?

Pulmonary embolism (PE) is the obstruction of pulmonary arteries, most commonly by blood clots originating from deep vein thrombosis in the legs or pelvis, representing the most serious and potentially fatal clinical presentation of venous thromboembolism. 1

Definition and Pathophysiology

PE occurs when thromboemboli block the pulmonary vasculature, creating an acute increase in pulmonary vascular resistance that can lead to right ventricular failure—the primary cause of death in severe cases. 2, 3

  • Deep vein thrombosis and pulmonary embolism are manifestations of the same disease entity: venous thromboembolic disease 3
  • Over 70% of proven PE cases have proximal leg thrombus as the source, though this is usually clinically undetectable 1
  • In up to 50% of PE patients, no deep vein thrombosis is found on imaging, suggesting either complete embolization of the source thrombus or alternative origins 4

Epidemiology and Clinical Impact

PE is the third most frequent cardiovascular disease with devastating mortality: untreated PE carries approximately 30% mortality, which drops to 2-8% with adequate anticoagulation. 1

  • Annual incidence ranges from 100-200 per 100,000 inhabitants in Europe 1
  • Over 317,000 deaths were related to venous thromboembolism in six European Union countries in 2004 1
  • 59% of PE-related deaths occur undiagnosed during life, and only 7% are correctly diagnosed before death 1
  • Risk approximately doubles with each decade after age 40 1
  • Three-month mortality in acute PE ranges from 9-17.5%, with sustained hypotension conferring 52.4% mortality versus 14.7% in normotensive patients 1, 2

Clinical Presentation Spectrum

PE presents across a wide severity spectrum, requiring classification for appropriate management 1:

Massive PE

  • Defined by shock and/or hypotension (systolic blood pressure <90 mmHg or pressure drop of 40 mmHg for >15 minutes not caused by arrhythmia, hypovolemia, or sepsis) 1
  • Right ventricular failure from acute pressure overload is the mechanism of death 2, 3

Submassive PE

  • Non-massive PE with echocardiographic evidence of right ventricular dysfunction 1
  • This subgroup has different prognosis than those with normal right ventricular function 1

Non-massive PE

  • All cases without shock or hypotension 1

Hemodynamic Consequences

The abrupt increase in pulmonary vascular resistance causes right ventricular dilation and dysfunction, with the interventricular septum bowing leftward and impairing left ventricular filling. 3

  • Pulmonary artery pressure increases when >30-50% of the total cross-sectional area of the pulmonary arterial bed is occluded 3
  • Systemic hypotension compromises coronary perfusion to the overloaded right ventricle, potentially causing right ventricular ischemia 2

Associated Complications

Acute Complications

  • Sudden death can be the first presentation 1
  • Pulmonary infarction (actually alveolar hemorrhage) causes hemoptysis, pleuritis, and pleural effusion 3, 5
  • Distal emboli cause pleural irritation even without significant hemodynamic effects 5

Chronic Complications

  • Chronic thromboembolic pulmonary hypertension develops in approximately 3.8% of patients within 2 years after initial PE 2, 3
  • Post-thrombotic syndrome 6

Non-Thrombotic Causes

While thrombotic occlusion is the primary etiology, PE can result from other sources 2:

  • Septic embolism (right-sided endocarditis, infected catheters) 2
  • Fat embolism (long bone fractures, orthopedic procedures) 2
  • Air embolism (lethal volume: 200-300 ml at 100 ml/s) 2
  • Amniotic fluid embolism (1/8,000-1/80,000 pregnancies with 80% maternal mortality) 2
  • Tumor embolism (seen in up to 26% of autopsies, rarely diagnosed ante-mortem) 2
  • Foreign material from broken catheters or medical devices 2

Diagnostic Challenge

PE is both underdiagnosed and overdiagnosed in clinical practice: 70% of fatal PE cases were not suspected clinically, while 63% of clinically diagnosed PE cases were not confirmed at autopsy. 1

  • The presentation is variable and nonspecific, making diagnosis challenging 7
  • PE may remain asymptomatic or be an incidental finding 1
  • The prevalence at autopsy (12-15% in hospitalized patients) has remained unchanged over three decades 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Pulmonary Embolism Causes and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Pulmonary Embolism Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Pulmonary Embolism-Related Pleural Effusion

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Epidemiology, Pathophysiology, Stratification, and Natural History of Pulmonary Embolism.

Techniques in vascular and interventional radiology, 2017

Related Questions

Why do pulmonary embolisms (PEs) cause leukocytosis?
What is pulmonary embolism and how is it treated?
What is the optimal management strategy for a 37-year-old woman with a history of unprovoked proximal Deep Vein Thrombosis (DVT) who develops a new Pulmonary Embolism (PE) despite adherence to rivaroxaban (Xarelto) (rivaroxaban) 20 mg daily for secondary prevention?
Is fluid in the lung more likely due to pulmonary embolism or pneumonia in an afebrile patient on antibiotics for 8 days with a history of ostomy surgery and large blood clots in both legs?
What is the pathophysiology, diagnosis, and treatment of pulmonary embolism (PE)?
What is the next line of antibiotic treatment for a patient in their late 50s with a Urinary Tract Infection (UTI) culture showing Escherichia coli (E. coli) resistant to ciprofloxacin and Trimethoprim-Sulfamethoxazole (TMP-SMX)?
Is topical finasteride effective for promoting hair growth in adult males with androgenetic alopecia?
Can a patient with androgenetic alopecia make topical finasteride (a 5-alpha-reductase inhibitor) from oral finasteride tablets?
Can cefuroxime (a second-generation cephalosporin) and clarithromycin (a macrolide antibiotic) be used to cover common pathogens in a patient with a complicated urinary tract infection (UTI)?
What is the perfusion index and its significance in clinical practice, particularly in patients with compromised oxygen delivery?
What antibiotic can be safely started in an elderly patient with a history of seizures on Keppra (levetiracetam), who recently received Augmentin (amoxicillin-clavulanate) for 10 days for a dental abscess and now presents with fever, productive cough, and diarrhea?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.